Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This study found no significant benefit of platelet-rich plasma injections over placebo in improving erectile function in patients with mild to moderate erectile dysfunction.

This study found that use of 5-alpha reductase inhibitors for benign prostatic hyperplasia was not associated with an increased risk of hip fracture in men.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study found that initiation of 5α-reductase inhibitors like finasteride is not associated with an increased risk of depression in veterans, suggesting depression may be linked to underlying health conditions instead.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This study found that cromakalim and pinacidil significantly inhibited porcine detrusor muscle contractions, suggesting these ATP-sensitive potassium channel openers may have potential in treating certain bladder diseases.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.

This review focuses on recent advancements in understanding and treating ischemic and nonischemic priapism, but does not present new clinical results.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This review discusses the role of norepinephrine release and protein kinase C activation in the development of benign prostatic hypertrophy, suggesting potential targets for new therapies, but it reports no new clinical results.

Tamsulosin works faster, but both drugs have similar effects after 6 months.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This article reviews the Clinical Pearls presentation format introduced at the American College of Physicians' 2001 meeting for its effectiveness in applying practical clinical tips, but provides no new empirical results.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

This study found that finasteride treatment decreased VEGF expression in the prostate tissue of patients with benign prostatic hyperplasia, although it did not affect vascular density or serum VEGF levels.

This study found that in beagles with benign prostate hyperplasia, finasteride treatment increased blood volume and decreased vessel leakiness in the prostate's parenchymal zone as shown by dynamic contrast-enhanced MRI.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This study found that terazosin hydrochloride, when used with finasteride, improved prostate volume and lowered blood pressure in BPH patients with high blood pressure, although the overall treatment effect was not significantly different from controls.

This article discusses the potential use of 5α-reductase inhibitors in dermatology and reports no new clinical results; the authors suggest further exploration of their dermatological applications.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

This study found that terazosin, finasteride, or their combination were effective in treating symptoms of benign prostatic hyperplasia.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.